TY - JOUR
T1 - Health Supervision for Children With 22q11.2 Deletion Syndrome
T2 - Clinical Report
AU - Council on Genetics
AU - Scheuerle, Angela E.
AU - Geleske, Timothy A.
AU - Merchant, Nadia
AU - Goldenberg, Paula C.
AU - Vergano, Samantha
AU - Holm, Ingrid A.
AU - Jones, Kelly
AU - Kalish, Jennifer
AU - Monteil, Danielle C.
AU - Pritchard, Amanda Barone
AU - Rasmussen, Sonja A.
AU - Russell, Bianca
AU - Santoro, Stephanie L.
AU - Trapane, Pamela
AU - Weaver, Kathryn Nicole
N1 - Publisher Copyright:
Copyright © 2025 by the American Academy of Pediatrics.
PY - 2025/8
Y1 - 2025/8
N2 - 22q11.2 deletion syndrome is the most frequent chromosomal microdeletion syndrome, with an estimated frequency of about 1/4000 in children younger than 1 year. Associated features in neonates and infants are conotruncal heart defects, interrupted aortic arch type B, cleft palate, hypocalcemia (which can present as seizures), feeding problems, developmental delay, and immune system abnormalities. Older children, adolescents, and adults may have neurocognitive impairments and/or speech disorders. Psychiatric diagnoses are more common than in the general population. Newborn infants may have a positive newborn screening for severe combined immunodeficiency (SCID). Genetic diagnosis is confirmed by chromosome microarray. This document is intended to provide guidance for health care providers to help identify individual patients at high risk of developing serious sequelae and to enable intervention before complications develop.
AB - 22q11.2 deletion syndrome is the most frequent chromosomal microdeletion syndrome, with an estimated frequency of about 1/4000 in children younger than 1 year. Associated features in neonates and infants are conotruncal heart defects, interrupted aortic arch type B, cleft palate, hypocalcemia (which can present as seizures), feeding problems, developmental delay, and immune system abnormalities. Older children, adolescents, and adults may have neurocognitive impairments and/or speech disorders. Psychiatric diagnoses are more common than in the general population. Newborn infants may have a positive newborn screening for severe combined immunodeficiency (SCID). Genetic diagnosis is confirmed by chromosome microarray. This document is intended to provide guidance for health care providers to help identify individual patients at high risk of developing serious sequelae and to enable intervention before complications develop.
UR - http://www.scopus.com/inward/record.url?scp=105012903642&partnerID=8YFLogxK
U2 - 10.1542/peds.2025-072717
DO - 10.1542/peds.2025-072717
M3 - Article
C2 - 40685150
AN - SCOPUS:105012903642
SN - 0031-4005
VL - 156
JO - Pediatrics
JF - Pediatrics
IS - 2
M1 - e2025072717
ER -